Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
暂无分享,去创建一个
[1] I. Schmidt-Wolf,et al. Lymphokine-activated killer cell activity after cryopreservation. , 1989, Journal of immunological methods.
[2] S. Fosså,et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. , 1989, European journal of cancer & clinical oncology.
[3] W. Linehan,et al. Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.
[4] A. Komiyama,et al. Induction of lymphokine‐activated killer and natural killer cell activities from cryopreserved lymphocytes , 1988, Transfusion.
[5] T. Eberlein,et al. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. , 1988, Cancer research.
[6] R. Bechhofer,et al. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. , 1988, Cancer research.
[7] R. Bechhofer,et al. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. , 1988, Journal of biological response modifiers.
[8] L. Lanier,et al. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[10] G. Marshall,et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.
[11] B. V. van Krimpen,et al. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1. , 1987, Journal of immunology.
[12] T. Seyama,et al. Cryopreservation of human lymphocytes for assessment of lymphocyte subsets and natural killer cytotoxicity. , 1986, Journal of immunological methods.
[13] S. Rosenberg,et al. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. , 1985, Journal of immunology.
[14] J. Gratama,et al. NATURAL IMMUNITY AND GRAFT‐VERSUS‐HOST DISEASE , 1985 .
[15] S. Rosenberg,et al. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2 , 1984, The Journal of experimental medicine.
[16] P. Greenberg,et al. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2 , 1982, The Journal of experimental medicine.
[17] S. Rosenberg,et al. Lymphokine-Activated Killer Cells , 1989 .
[18] S. Rosenberg. Immunotherapy of cancer using interleukin 2: current status and future prospects. , 1988, Immunology today.
[19] P. Hersey,et al. 'Nonspecific' MHC-unrestricted killer cells and their receptors. , 1987, Immunology today.